Abstract
The purpose of the study was to determine which factors correlate directly with response to vaccination in such a group of subjects with non-protective HI antibody titers before vaccination. Two vaccines were used, a subunit virus vaccine adjuvanted with MF59 and a split virus vaccine. The analysis indicated that immunization with vaccine adjuvanted with MF59 was an independent variable for immune response against A/H3N2 (OR: 3.51; 95% CI: 1.81–6.79) and B (OR: 2.31; 95% CI: 1.37–3.89). The results suggest that antibody response to vaccine is satisfactory in elderly people previously lacking a protective antibody titer, and that the adjuvanted vaccine reveals a better immunogenicity.
This is a preview of subscription content, log in via an institution to check access.
References
Vu T, farish S, Jenkins M, Kelly H (2002) A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831–1836
De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus ADME (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115:63–73
Remarque EJ, De Jong JM, Van Der Klis RJ, Masurel N, Ligthart GJ (1999) Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol: 34:109–115
Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R (1999) Influenza vaccines: antibody responses to split MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 15:573–576
Beyer WEP, Palache AM, Osterhaus ADME (1998) Comparison of serology and reactogenicity between influenza subunit vaccine and whole virus or split virus: a review and meta-analysis of the literature. Clin Drug Invest 15:1–12
Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus ADME (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103:125–132
Potter CW (2001) A history of influenza. J Appl Microbiol 91:572–579
Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937–1943
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baldo, V., Baldovin, T., Floreani, A. et al. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 21, 843–845 (2006). https://doi.org/10.1007/s10654-006-9071-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-006-9071-4